EP1928490B1 - Compositions et procedes d'utilisation de mutants des chondroitinases abci - Google Patents

Compositions et procedes d'utilisation de mutants des chondroitinases abci Download PDF

Info

Publication number
EP1928490B1
EP1928490B1 EP06815505A EP06815505A EP1928490B1 EP 1928490 B1 EP1928490 B1 EP 1928490B1 EP 06815505 A EP06815505 A EP 06815505A EP 06815505 A EP06815505 A EP 06815505A EP 1928490 B1 EP1928490 B1 EP 1928490B1
Authority
EP
European Patent Office
Prior art keywords
enzyme
chondroitinase abci
nervous system
chondroitinase
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06815505A
Other languages
German (de)
English (en)
Other versions
EP1928490A2 (fr
EP1928490A4 (fr
EP1928490B8 (fr
Inventor
Anthony O. Caggiano
Jennifer Iaci
Andrea Vecchione
Elizabeth Markensohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of EP1928490A2 publication Critical patent/EP1928490A2/fr
Publication of EP1928490A4 publication Critical patent/EP1928490A4/fr
Publication of EP1928490B1 publication Critical patent/EP1928490B1/fr
Application granted granted Critical
Publication of EP1928490B8 publication Critical patent/EP1928490B8/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Proteoglycans major constituents of the extracellular matrix, are known to be present in large amounts in glial scar tissue and to inhibit recovery following spinal cord injuries (Fawcett & Asher, 1999). Enzymes that are capable of digesting glial scar tissue are an important target for the development of spinal cord injury (SCI) therapeutics.
  • Chondroitinase ABCI EC 4.2.2.4; cABCI
  • cABCI is a bacterial enzyme that catalyzes the digestion of sulfated chondroitin and dermatan side chains of proteoglycans. This enzyme has been shown to promote functional recovery after spinal cord injury (Bradbury et al., 2002; Caggiano et al., 2005 and WO 2004/103299 ).
  • the spinal cord is made up of nerve fibers. Damage to the central nervous system, including the spinal cord, results in a loss of function. Depending upon the type of injury to the central nervous system, the loss of function may manifest itself in loss of sensory, motor or autonomic function or a combination thereof. Sensory functions include the ability to feel sensations, like pain. Motor functions include the ability to voluntarily move your body. Autonomic functions include involuntary body functions, for example the ability to sweat and breathe.
  • SCI spinal cord injuries
  • contusions bruising of the spinal cord
  • compression injuries caused by prolonged pressure on the spinal cord.
  • a cavity or hole often forms in the center of the spinal cord.
  • nerve cells or neurons of the peripheral nervous system (PNS)
  • neurons of the central nervous system (CNS) do not regenerate after injury.
  • CSPGs chondroitin sulfate proteoglycans
  • neurite refers to both axon and dendrite structures.
  • the process of sprouting neurites is essential in neural development and regeneration, especially after physical injury or disease has damaged neuronal cells. Neurites elongate profusely during development both in the central and peripheral nervous systems of all animal species. This phenomenon pertains to both axons and dendrites.
  • CAMs cell adhesion molecules
  • FN extracellular matrix protein fibronectin
  • U.S. Patent No. 5,792,743 discloses novel polypeptides and methods for promoting neural growth in the CNS of a mammal by administering a soluble neural CAM, a fragment thereof, or a Fc-fusion product thereof.
  • U.S. Patent No. 6,313,265 discloses synthetic polypeptides containing the pharmacologically active regions of CAMs that can be used in promoting nerve regeneration and repair in both peripheral nerve injuries as well as lesions in the CNS. While helpful, the use of regenerative proteins alone may not be sufficient to effect repair of a damaged nervous system.
  • ECMs extracellular matrices
  • the action of enzymes and other polypeptides which degrade components of the extracellular matrix and basement membranes may facilitate the events of neural repair by a variety of mechanisms, including the release of bound cytokines and by increasing the permeability of the matrix, thereby enhancing the mobility of mediator molecules, growth factors and chemotactic agents, as well as the cells involved in the healing process.
  • U.S. Patent No. 5,997,863 discloses the use of glycosaminoglycans to manipulate cell proliferation and promote wound healing.
  • CSPGs Components of the inhibitory CSPGs have been identified as the glycosaminoglycans, chondroitin sulfate (CS) and dermatan sulfate (DS). Removal of these inhibitory molecules would allow neurites to regenerate and reinnervate an area after physical injury or disease, as well as to allow for the recovery of sensory, motor and autonomic functions.
  • chondroitinases can lyse and degrade CSPGs including, CS and DS.
  • chondroitinase ABC removed glycosaminoglycan (GAG) chains in and around lesioned areas of rat CNS in vivo.
  • GAGs glycosaminoglycan
  • the degradation of GAGs promoted expression of a growth-associated protein, GAP-43, indicating an increase in the ability of treated cells to regenerate.
  • GAP-43 glycosaminoglycan
  • this growth-associated protein is associated with regeneration in peripheral, but not central, nerve injuries.
  • Chondroitin sulfates are sulfated polysaccharides in linear chains of a repeated dissacharides. They range in molecular weight from about 10,000 to over 100,000 Da. Chondroitin sulfate substrates exist in different isomers designated by the appended letters A, B, and C (Hoffman et al., 1958). The repeating units are composed of uronic acid (GlcA or IdoA) and galactosamine, and are called galactosaminoglycans, and are one example of the glycosaminoglycans, typically abbreviated as GAG.
  • GAG chain species Although these GAG chain species have different repeating disaccharide regions, they are covalently bound through the so-called linkage region tetrasaccharide sequence (see below) to the serine residue in the GAG attachment consensus sequence (Glu/Asp-X-Ser-Gly) of respective core proteins.
  • Chondroitin A and C sulfates (ChS-A, ChS-C) are the most abundant GAGs and are found in cartilage, bone and heart valves. Chondroitin B (ChS-B, or, alternatively, dermatan sulfate) is expressed mostly in skin, blood vessels, and heart valves.
  • Chondroitinase AC that degrades mostly chondroitin A (ChA) and chondroitin C (ChC) (Yamagata et al., 1968)
  • Chondroitinase B that degrades chondroitin B (ChB)
  • Chondroitinase C that acts mostly on ChC
  • Chondroitinase ABC exhibits specificity against all three substrates - ChS-A, ChS-B and ChS-C (Yamagata et al., 1968, Michelacci et al., 1987).
  • Huang et al J. Mol. Biol. 328:623-634, 2003 discloses the crystal structure of ABCI and identifies the active site.
  • Prabhakar et al. uses SDM to characterise the active site of ABCI.
  • WO 2005/087920 describes certain modified ABCI enzymes for use in nerve regeneration after CNS or spinal cord injury.
  • One aspect of the present invention provides mutants of chondroitinase ABCI as defined in claim 1.
  • such chondroitinase ABCI mutants exhibit enhanced activity. In other preferred embodiments, such chondroitinase ABCI mutants exhibit enhanced resistance to inactivation, including inactivation from UV or heat exposure.
  • the chondroitinase ABCI mutant enzymes are selected from BC6 (SEQ ID NO:1), BE7 (SEQ ID NO:2), and BF4 (SEQ ID NO:3).
  • inventions of the present invention relate to a mutant enzyme of the invention for promoting neurological functional recovery, including sensory, motor and autonomic function, after central nervous system (“CNS”) injury or disease.
  • CNS central nervous system
  • Fig. 1 is a bar graph of the chondroitin lyase activity of wild-type, not-inactivated chondroitinase ABCI (normal), wild-type, inactivated (No Enz) and chondroitinase ABCI mutant enzymes of the present invention following UV exposure.
  • Fig 2 is a bar graph of the chondroitin lyase activity of wild-type, not-inactiviated chondroitinase ABCI (normal), wild-type, inactivated (No Enz) and chondroitinase ABCI mutant enzymes.
  • the term "about” means plus or minus 10% of the numerical value of the number with which it is being used. Therefore, about 50% means in the range of 45%-55%.
  • administering when used in conjunction with a therapeutic means to administer a therapeutic directly into or onto a target tissue or to administer a therapeutic to a patient whereby the therapeutic positively impacts the tissue to which it is targeted.
  • administering can include, but is not limited to, providing an enzyme into the CNS or onto the target tissue; providing an enzyme systemically to a patient by, e.g., intravenous injection whereby the therapeutic reaches the target tissue; providing an enzyme in the form of the encoding sequence thereof to the target tissue (e.g., by so-called gene-therapy techniques).
  • administering a composition may be accomplished by injection, topical administration, or by either method in combination with other known techniques.
  • animal as used herein includes, but is not limited to, humans and non-human vertebrates such as wild, domestic and farm animals.
  • the term “improves” is used to convey that the present invention changes either the appearance, form, characteristics and/or the physical attributes of the target to which it is being provided, applied or administered.
  • the change may be demonstrated by any of the following alone or in combination, including degradation of the CSPGs of the lesioned area of the spinal cord or within the CNS or restoring, in whole or in part, motor, sensory or autonomic function of the mammal.
  • inhibitor includes the administration of a compound of the present invention to prevent the onset of the symptoms, alleviating the symptoms, or eliminating the disease, condition or disorder.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • recombinant protein refers to a polypeptide of the present invention which is produced by recombinant DNA techniques, wherein generally, DNA encoding a polypeptide is inserted into a suitable expression vector which is in turn used to transform a host cell to produce the protein.
  • phrase "derived from”, with respect to a recombinant gene is meant to include within the meaning of "recombinant protein” those proteins having an amino acid sequence of a native protein, or an amino acid sequence similar thereto which is generated by mutations including substitutions and deletions (including truncation) of a naturally occurring form of the protein.
  • the term "therapeutic” means an agent utilized to treat, combat, ameliorate, prevent or improve an unwanted condition or disease of a patient.
  • embodiments of the present invention are directed to the treatment of the central nervous system, such as degradation of the CSPGs of the lesioned area of the spinal cord or within the CNS or restoration, in whole or in part, motor, sensory or autonomic function of the mammal.
  • a therapeutically effective amount or “effective amount, as used herein, may be used interchangeably and refer to an amount of a therapeutic compound component of the present invention.
  • a therapeutically effective amount of a therapeutic compound is a predetermined amount calculated to achieve the desired effect, i.e., to effectively treat an injury to the central nervous system.
  • a therapeutic compound comprising a therapeutically effective amount of chondroitinase which may be purified by a method of the present invention and formulated to provide a stable, active enzyme, is sufficient to degrade the CSPGs of the lesioned area of the spinal cord or an amount sufficient to restore, in whole or in part, motor, sensory or autonomic function of the mammal and may result in a regeneration of neurons in a central nervous system, such as by promoting axonal growth into an injured area.
  • beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease.
  • Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.
  • vector refers to a vehicle which can transport the nucleic acid molecules.
  • the nucleic acid molecules encoding the chondroitinase polypeptide are covalently linked to the vector nucleic acid.
  • the vector can be a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, or MAC.
  • Chondroitinase may be obtained from a microorganism that naturally expresses a chondroitinase; for example, but not limited to, E . coli, Proteus vulgaris or from the expression of a recombinant protein in a host cell.
  • the host cell can be a prokaryotic cell (such as E . coli ) or a eukaryotic cell (such as yeast, a mammalian cell or an insect cell).
  • the nucleotide sequence of chondroitinase ABCI is set forth as SEQ ID NO. 8 and the amino acid sequence of chondroitinase ABCI is set forth as SEQ ID NO. 9.
  • chondroitinase ABCI mutant enzymes are selected from BC6 (SEQ ID NO:1), BE7 (SEQ ID NO:2), and BF4 (SEQ ID NO:3).
  • Such enzymes may be formulated into pharmaceutical compositions and formulations. Suitable stable formulations and methods of purification are set forth in copending PCT Application No. US2005/017464 filed May 18, 2005 entitled “Methods of Purifying Chondroitinase and Stable Formulations Thereof".
  • One aspect of the present invention provides mutants of chondroitinase which exhibit enhanced activity.
  • chondroitinase ABCI mutants exhibit enhanced resistance to inactivation.
  • the chondroitinase ABCI mutant enzymes are selected from BC6 (SEQ ID NO:1), BE7 (SEQ ID NO:2), and BF4 (SEQ ID NO:3).
  • the method comprises altering the nucleotide sequence or amino acid sequence of chondroitinase ABCI, expressing the chondroitinase ABCI in a suitable vector and measuring the activity of the mutant enzyme.
  • a stable chondroitinase ABCI enzyme is provided.
  • the enzyme may exhibit increased resistance to inactivation under stressed conditions, including exposure to UV light or heat.
  • the enzyme exhibits increased stability compared to wild-type chondroitinase ABCI enzyme following a challenge by a stress.
  • enzymes of the present invention can be used for treating central nervous system injuries by administering a chondroitinase ABCI mutant enzyme.
  • the chondroitinase ABCI mutant enzyme is administered in a therapeutically effective amount.
  • the chondroitinase ABCI mutant enzyme is selected from the group consisting of BC6 (SEQ ID NO:1), BE7 (SEQ ID NO:2), and BF4 (SEQ ID NO:3).
  • Such central nervous system injuries may include, but are not limited to, spinal cord injuries.
  • enzymes of the present invention can be used for promoting neuronal outgrowth by administering a chondroitinase ABCI mutant enzyme.
  • the chondroitinase ABCI mutant enzyme is administered in a therapeutically effective amount.
  • the chondroitinase ABCI mutant enzyme is selected from the group consisting of BC6 (SEQ ID NO:1), BE7 (SEQ ID NO:2), and BF4 (SEQ ID NO:3).
  • chondroitinase ABCI mutant enzyme is administered in a therapeutically effective amount.
  • the enzymes of the present invention can be used to promote sensory, motor or autonomic neurological functional recovery following injury in or to the spinal cord.
  • Useful compositions include acceptable formulations of chondroitinase, more particularly sustained release formulations of chondroitinase.
  • the enzymes of the present invention can also be directed to promoting neurological functional recovery after a contusion injury to the spinal cord.
  • SCI spinal cord injuries
  • contusions bruising of the spinal cord
  • compression injuries caused by pressure on the spinal cord.
  • contusion injuries the most common type of injury, a cavity or hole often forms in the center of the spinal cord.
  • the treatments of the present disclosure delivery an effective amount of the mutant or other optional therapeutic agent to the CNS or the injured site of the CNS.
  • chondroitin sulphate proteoglycans including, but not limited to chondroitinase ABC TypeI , chondroitinase ABC TypeII , chondroitinase AC and chondroitinase B or mammalian enzymes with chondroitinase-like activity such as Hyal1, Hyal2, Hyal3, and Hyal4 can be administered preferably to the CNS, and more preferably to the lesions of the injured area of the CNS.
  • chondroitinase polypeptides can be produced by standard biological techniques or by chemical synthesis.
  • a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding the subject polypeptides can be cultured under appropriate conditions to allow expression of the peptide to occur.
  • the chondroitinase polypeptide may be secreted and isolated from a mixture of cells and medium containing the recombinant chondroitinase polypeptide.
  • purification methods wherein the chondroitinase is isolated in a pure form that is more stable and active than those methods currently used.
  • the peptide may be retained cytoplasmically by removing the signal peptide sequence from the recombinant chondroitinase gene and the cells harvested, lysed and the protein isolated by the purification methods described herein.
  • Chondroitinase may be administered topically, locally or systemically. Topical or local administration is preferable for greater control of application.
  • the chondroitinases singularly or in combination, can be mixed with an appropriate pharmaceutical carrier prior to administration.
  • Examples of generally used pharmaceutical carriers and additives are conventional diluents, binders, lubricants, coloring agents, disintegrating agents, buffer agents, isotonizing fatty acids, isotonizing agents, preservants, anesthetics, surfactants and the like, and are known to those skilled in the art.
  • Specifically pharmaceutical carriers that may be used are dextran, sucrose, lactose, maltose, xylose, trehalose, mannitol, xylitol, sorbitol, inositol, serum albumin, gelatin, creatinine, polyethlene glycol, non-ionic surfactants (e.g. polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hardened castor oil, sucrose fatty acid esters, polyoxyethylene polyoxypropylene glycol) and similar compounds.
  • Pharmaceutical carriers may also be used in combination, such as polyethylene glycol and/or sucrose, or polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitan monooleate (20 E. 0.) is particularly preferred.
  • a treatment regimen may be carried out by a means of administering a mutant chondroitinase ABCI enzyme of the present invention.
  • the treatment regiment may further comprise administering chondroitinase ABCII, chondroitinase AC and chondroitinase B or mammalian enzymes with chondroitinase-like activity such as Hyal1, Hyal2, Hyal3, Hyal4 and PH2O to the lesions of the injured area of the CNS.
  • the mode of administration, the timing of administration and the dosage are carried out such that the functional recovery from impairment of the CNS is enhanced by the promotion of neurite outgrowth.
  • the effective amount of chondroitinase can be administered in a single dosage, two dosages or a plurality of dosages.
  • the dosage may be administered at any time, in one embodiment, the dosage is administered within 12 hours after injury, or as soon as is feasible.
  • the dosage is administered to an injured mammal in one, two or a plurality of dosages; such dosages would be dependant on the severity of the injury and the amount of CSPGs present in the glial scarring.
  • a plurality of dosages may be delivered on a daily, weekly, or bi-weekly basis. The delivery of the dosages may be by means of catheter or syringe.
  • the treatment can be administered during surgery to allow direct application to the glial scar.
  • a pharmaceutical composition comprising a compound, as defined above, and a pharmaceutically acceptable carrier or diluent, or an effective amount of a pharmaceutical composition comprising a compound as defined above can be used.
  • the compounds of the present invention can be administered in the conventional manner by any route where they are active. Administration can be systemic, topical, or oral. For example, administration can be, but is not limited to, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, buccal, or ocular routes, or intravaginally, by inhalation, by depot injections, or by implants.
  • modes of administration for the compunds of the present invention can be, but are not limited to, sublingual, injectable (including short-acting, depot, implant and pellet forms injected subcutaneously or intramuscularly), or by use of vaginal creams, suppositories, pessaries, vaginal rings, rectal suppositories, intrauterine devices, and transdermal forms such as patches and creams.
  • Specific modes of administration will depend on the indication.
  • the selection of the specific route of administration and the dose regimen is to be adjusted or titrated by the clinician according to methods known to the clinician in order to obtain the optimal clinical response.
  • the amount of compound to be administered is that amount which is therapeutically effective.
  • the dosage to be administered will depend on the characteristics of the subject being treated, e.g., the particular animal treated, age, weight, health, types of concurrent treatment, if any, and frequency of treatments, and can be easily determined by one of skill in the art (e.g., by the clinician).
  • compositions containing the compounds of the present invention and a suitable carrier can be solid dosage forms which include, but are not limited to, tablets, capsules, cachets, pellets, pills, powders and granules; topical dosage forms which include, but are not limited to, solutions, powders, fluid emulsions, fluid suspensions, semi-solids, ointments, pastes, creams, gels and jellies, and foams; and parenteral dosage forms which include, but are not limited to, solutions, suspensions, emulsions, and dry powder; comprising an effective amount of an enzyme of the present invention.
  • the active ingredients can be contained in such formulations with pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
  • pharmaceutically acceptable diluents fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
  • the means and methods for administration are known in the art and an artisan can refer to various pharmacologic references for guidance. For example, Modern Pharmaceutics, Banker & Rhodes, Marcel Dekker, Inc. (1979 ); and Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 6th Edition, MacMillan Publishing Co., New York (1980 ) can be
  • the compounds of the present invention can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • the compounds can be administered by continuous infusion subcutaneously over a period of about 15 minutes to about 24 hours.
  • Formulations for injection can be presented in unit dosage form, e.g. , in ampoules or in multi-dose containers, with an added preservative.
  • the compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the compounds can be formulated readily by combining these compounds with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • Pharmaceutical preparations for oral use can be obtained by adding a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients include, but are not limited to, fillers such as sugars, including, but not limited to, lactose, sucrose, mannitol, and sorbitol; cellulose preparations such as, but not limited to, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidone (PVP).
  • disintegrating agents can be added, such as, but not limited to, the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores can be provided with suitable coatings.
  • suitable coatings can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions which can be used orally include, but are not limited to, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as, e.g., lactose, binders such as, e.g., starches, and/or lubricants such as, e.g., talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers can be added. All formulations for oral administration should be in dosages suitable for such administration.
  • compositions can take the form of, e.g., tablets or lozenges formulated in a conventional manner.
  • the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or
  • the compounds of the present invention can also be formulated in rectal compositions such as suppositories or retention enemas, e.g. , containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds of the present invention can also be formulated as a depot preparation.
  • Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the present invention for example, can be applied to a plaster, or can be applied by transdermal, therapeutic systems that are consequently supplied to the organism.
  • compositions of the compounds also can comprise suitable solid or gel phase carriers or excipients.
  • suitable solid or gel phase carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as, e.g. , polyethylene glycols.
  • the compounds of the present invention can also be administered in combination with other active ingredients, such as, for example, adjuvants, protease inhibitors, or other compatible drugs or compounds where such combination is seen to be desirable or advantageous in achieving the desired effects of the methods described herein.
  • active ingredients such as, for example, adjuvants, protease inhibitors, or other compatible drugs or compounds where such combination is seen to be desirable or advantageous in achieving the desired effects of the methods described herein.
  • the present example illustrates exemplary chondroitinase mutant enzymes of the present invention. All nucleotide and amino acids are indicated as the wild-type and then the mutant version (Wild-type to Mutant).
  • Mutant ABCI enzyme Nucleotide sequence Amino Acid sequence BC6 (SEQ ID NO. 1) T1206 to C1206 E403 to G403 C1114 to A1114 W372 to C372 BE7 (SEQ ID NO. 2) G1925 to T1925 S642 to I642 T2226 to G2226 I742 to M742 BF4 (SEQ ID NO. 3) T2160 to A2160 N720 to K720e BC9 (SEQ ID NO.
  • the present example illustrates the chondroitin lyase activity of exemplary chondroitinase ABCI mutants according to the present invention following UV exposure.
  • Mutant chondroitinase ABIC genes were generated and transformed into bacteria. Bacteria were grown and the mutagenized chondroitinase expressed. The chondroitinase were then exposed to UV light and their chondroitin lyase activity measured. As depicted in Fig. 1 ; clone BC6 (SEQ ID NO:1), BE7 (SEQ ID NO:2) and BF4 (SEQ ID NO:3) exhibited greater chondroitin lyase activity following exposure to UV light as compared to control.
  • the present example illustrates the chondroitin lyase activity of exemplary chondroitinase ABCI mutants.
  • the chondroitinase lyase activity of Clone BC9, Clone BC7, Clone RD4 and Clone BE11 under normal (i.e., non-stressed) conditions was measured and exhibited decreased activity as compared to control an wild-type chondroitinase ABCI, as depicted in Fig. 2 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (18)

  1. Une enzyme chondroïtinase ABCI mutante, ladite enzyme comprenant SEQ ID NO : 1, SEQ ID NO : 2 ou SEQ ID NO : 3.
  2. L'enzyme chondroïtinase ABCI mutante de la revendication 1, ladite enzyme comprenant SEQ ID NO : 1.
  3. L'enzyme chondroïtinase ABCI mutante de la revendication 1, ladite enzyme comprenant SEQ ID NO : 2.
  4. L'enzyme chondroïtinase ABCI mutante de la revendication 1, ladite enzyme comprenant SEQ ID NO : 3.
  5. Une enzyme chondroïtinase ABCI mutante telle que revendiquée dans l'une quelconque des revendications 1 à 4, destinée à être utilisée pour traiter une lésion du système nerveux central.
  6. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 5, ladite enzyme étant destinée à l'administration suite à une lésion de type contusion du système nerveux central.
  7. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 5, ladite enzyme étant destinée à l'administration suite à une lésion qui n'est pas de type contusion du système nerveux central.
  8. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 5, ladite enzyme étant destinée à l'administration suite à une lésion de la moelle épinière.
  9. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon l'une quelconque des revendications 5 à 8, ladite enzyme étant formulée pour une administration locale.
  10. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 9, ladite enzyme étant formulée pour une administration intrathécale.
  11. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon l'une quelconque des revendications 5 à 8, ladite enzyme étant formulée pour une administration topique.
  12. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 5, ladite enzyme favorisant l'excroissance neuronale.
  13. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 6, ladite enzyme favorisant l'excroissance neuronale.
  14. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 7, ladite enzyme favorisant l'excroissance neuronale.
  15. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 8, ladite enzyme favorisant l'excroissance neuronale.
  16. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon l'une quelconque des revendications 12 à 15, ladite enzyme étant formulée pour une administration locale.
  17. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon la revendication 16, ladite enzyme étant formulée pour une administration intrathécale.
  18. L'enzyme chondroïtinase ABCI mutante destinée à être utilisée dans le traitement d'une lésion du système nerveux central selon l'une quelconque des revendications 12 à 15, ladite enzyme étant formulée pour une administration topique.
EP06815505A 2005-09-26 2006-09-26 Compositions et procedes d'utilisation de mutants des chondroitinases abci Active EP1928490B8 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72062805P 2005-09-26 2005-09-26
PCT/US2006/037554 WO2007038548A2 (fr) 2005-09-26 2006-09-26 Compositions et procedes d'utilisation de mutants des chondroitinases abci

Publications (4)

Publication Number Publication Date
EP1928490A2 EP1928490A2 (fr) 2008-06-11
EP1928490A4 EP1928490A4 (fr) 2010-03-31
EP1928490B1 true EP1928490B1 (fr) 2012-08-29
EP1928490B8 EP1928490B8 (fr) 2012-10-03

Family

ID=37900402

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06815505A Active EP1928490B8 (fr) 2005-09-26 2006-09-26 Compositions et procedes d'utilisation de mutants des chondroitinases abci

Country Status (7)

Country Link
US (7) US7485295B2 (fr)
EP (1) EP1928490B8 (fr)
JP (1) JP5189985B2 (fr)
AU (1) AU2006294755B2 (fr)
CA (1) CA2623635C (fr)
ES (1) ES2393748T3 (fr)
WO (1) WO2007038548A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE500842T1 (de) 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
ES2366333T3 (es) * 2002-08-15 2011-10-19 Acorda Therapeutics, Inc. Proteína quimérica.
MX348062B (es) 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
WO2004103299A2 (fr) * 2003-05-16 2004-12-02 Acorda Therapeutics, Inc. Compositions et methodes de traitement de blessures du systeme nerveux central
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA06013345A (es) * 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
EP1928490B8 (fr) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
EP2042190A4 (fr) 2006-05-19 2012-05-30 Aichi Prefecture Agent de traitement de lésions cérébrales
AU2007307736C1 (en) 2006-10-10 2014-04-10 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
CN112126606B (zh) * 2020-10-18 2022-09-30 山东大学 一株发光杆菌qa16及其培养方法与应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270194A (en) * 1989-08-31 1993-12-14 Instrumentation Laboratory Spa Stabilized glucose oxidase from Aspergillus Niger
WO1991006303A1 (fr) 1989-10-27 1991-05-16 Case Western Reserve University Inhibition de la croissance cellulaire par l'utilisation de sulfate de keratane, de sulfate de chondroitine, de sulfate de dermatane et autres glycanes
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5679650A (en) 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5496718A (en) * 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物
US7008783B1 (en) * 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
CA2161125A1 (fr) 1993-04-23 1994-11-10 Michael Joseph Ryan Clonage et expression de chondroitinase i et ii provenant de p. vulgaris
US5578480A (en) 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
US6248562B1 (en) * 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO1995013091A1 (fr) 1993-11-12 1995-05-18 International Technology Management Associates, Ltd. Procedes pour la reparation de tissu conjonctif
US5498536A (en) * 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
EP0704532B1 (fr) 1994-06-10 2002-09-11 United States Surgical Corporation Protéines chimériques recombinantes et procédés pour leur utilisation
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6093563A (en) * 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US6326166B1 (en) * 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
AU4658596A (en) 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
US5792743A (en) 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6313265B1 (en) 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
US5869301A (en) * 1995-11-02 1999-02-09 Lockhead Martin Energy Research Corporation Method for the production of dicarboxylic acids
JP3702450B2 (ja) 1996-12-18 2005-10-05 ニプロ株式会社 乳酸脱水素酵素測定用試薬
US6200564B1 (en) * 1997-04-11 2001-03-13 J. Thomas Lamont Pharmaceutical compositions containing chondroitinase and uses therefor
EP0875253B1 (fr) 1997-05-02 2005-04-06 Seikagaku Corporation Compositionsde chondroitinase
JP4172842B2 (ja) 1997-05-02 2008-10-29 生化学工業株式会社 コンドロイチナーゼ組成物
EP0900569B1 (fr) * 1997-08-22 2002-10-02 Seikagaku Corporation Médicament destiné au traitement d'un disque intervertébral blessé par hernie
US20010006630A1 (en) 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6153187A (en) * 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
DK1025227T3 (da) 1997-10-17 2006-05-01 Genentech Inc Humane TOLL-homologer
AU2662799A (en) 1998-02-13 1999-08-30 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
JP2002505873A (ja) 1998-03-13 2002-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮増殖因子２
AU3006899A (en) 1998-03-13 1999-09-27 Biomarin Pharmaceutical Inc. Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
JP2003527822A (ja) * 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
WO2000020021A1 (fr) * 1998-10-06 2000-04-13 Stryker Corporation Reparation du larynx, de la trachee et d'autres tissus fibrocartilagineux
WO2000062067A1 (fr) 1999-02-28 2000-10-19 Washington University Nouvelles molecules de transduction et leurs procedes d'utilisation
EP1169350A2 (fr) 1999-04-02 2002-01-09 Eli Lilly And Company COMPOSITIONS hOB-BP2h, LEURS TECHNIQUES ET LEURS UTILISATIONS
SE9901428D0 (sv) 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
CA2376379C (fr) 1999-06-08 2007-08-07 Regeneron Pharmaceuticals, Inc. Polypeptides chimeriques modifies a pharmacocinetique amelioree
WO2001039795A2 (fr) 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation de la proliferation de fibroblastes
ATE466882T1 (de) 2000-01-12 2010-05-15 Univ Yale Nogo rezeptor-vermittelte blockade des axonalen wachstums
WO2002076503A1 (fr) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
CA2412626C (fr) 2000-06-22 2013-10-22 Amgen Inc. Molecules il-17 et leurs utilisations
EP1343528A2 (fr) 2000-11-02 2003-09-17 Research Foundation of City University of New York Procedes de stimulation de la regeneration et de la reparation du systeme nerveux par inhibition de la phosphodiesterase de type 4
EP1343517A2 (fr) 2000-12-12 2003-09-17 Enkam Pharmaceuticals A/S Composes de liaison de n-cam et de liaison de ligands de n-cam favorisant la survie
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
GB0103174D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
WO2002065136A2 (fr) 2001-02-15 2002-08-22 University Of Chicago Cribles a base de levure pour le traitement de maladies humaines
CA2367636C (fr) 2001-04-12 2010-05-04 Lisa Mckerracher Proteines de fusion
AU2002311535A1 (en) 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding protein kinases
BR0211888A (pt) * 2001-08-13 2004-08-24 Univ Florida Res Foudantion In Materiais e métodos para promoção de reparo de tecido nervoso
US20030049258A1 (en) 2001-09-11 2003-03-13 Martin Ungerer Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
WO2003031578A2 (fr) 2001-10-09 2003-04-17 Immunex Corporation Lectines de type c mammiferes
US20030127812A1 (en) 2002-01-04 2003-07-10 Charles Mehrmann Bi-directional sliding board
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
ATE500842T1 (de) 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
EP1521523A4 (fr) 2002-05-20 2006-04-19 Univ Texas Procedes et compositions pour la delivrance d'enzymes et de molecules d'acide nucleique dans le cerveau, l'os, et autres tissus
AU2003243396A1 (en) 2002-06-03 2003-12-19 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US7163545B2 (en) * 2002-07-29 2007-01-16 Mayo Foundation For Medical Education And Research Spinal cord surgical implant
JP4527950B2 (ja) 2002-08-09 2010-08-18 シスメックス株式会社 脂質測定試薬
US7074581B2 (en) * 2002-08-09 2006-07-11 Sysmex Corporation Reagent for assaying lipid
PL375301A1 (en) * 2002-08-10 2005-11-28 Biogen Idec Ma Inc. Nogo receptor antagonists
ES2366333T3 (es) 2002-08-15 2011-10-19 Acorda Therapeutics, Inc. Proteína quimérica.
JP2004113166A (ja) 2002-09-27 2004-04-15 Mitsui Chemicals Inc ハロペルオキシダ−ゼ活性の安定化方法
MX348062B (es) 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
AU2004247025B8 (en) 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
WO2004103299A2 (fr) 2003-05-16 2004-12-02 Acorda Therapeutics, Inc. Compositions et methodes de traitement de blessures du systeme nerveux central
EP1737954A2 (fr) 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Chondroitinase abc i recombinante et ses utilisations
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
EP1928490B8 (fr) * 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
JP5092329B2 (ja) 2006-09-26 2012-12-05 栗田工業株式会社 短波長紫外線放電灯及び紫外線照射処理装置
AU2007307736C1 (en) 2006-10-10 2014-04-10 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants

Also Published As

Publication number Publication date
AU2006294755B2 (en) 2012-04-19
US20180066245A1 (en) 2018-03-08
EP1928490A2 (fr) 2008-06-11
AU2006294755A1 (en) 2007-04-05
US8236302B2 (en) 2012-08-07
US20070104703A1 (en) 2007-05-10
US20170009222A1 (en) 2017-01-12
WO2007038548A3 (fr) 2009-05-07
US20090104176A1 (en) 2009-04-23
EP1928490A4 (fr) 2010-03-31
CA2623635C (fr) 2013-04-02
CA2623635A1 (fr) 2007-04-05
JP5189985B2 (ja) 2013-04-24
US10323240B2 (en) 2019-06-18
US20150190483A1 (en) 2015-07-09
US9834764B2 (en) 2017-12-05
EP1928490B8 (fr) 2012-10-03
US8852583B2 (en) 2014-10-07
ES2393748T3 (es) 2012-12-27
JP2009509532A (ja) 2009-03-12
US20100239557A1 (en) 2010-09-23
US7485295B2 (en) 2009-02-03
WO2007038548A2 (fr) 2007-04-05
US20120308547A1 (en) 2012-12-06
US9402886B2 (en) 2016-08-02
US7731956B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
US10323240B2 (en) Compositions and methods of using chondroitinase ABCI mutants
US9987340B2 (en) Compositions and methods of using chondroitinase ABCI mutants
AU2016206267B2 (en) Compositions and methods of using chondroitinase abci mutants
AU2014200000B2 (en) Compositions and methods of using chondroitinase abci mutants

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080326

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20090507

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 1/20 20060101ALI20090511BHEP

Ipc: C12N 9/00 20060101AFI20090511BHEP

Ipc: C12N 9/88 20060101ALI20090511BHEP

Ipc: C07H 21/04 20060101ALI20090511BHEP

Ipc: C12N 15/00 20060101ALI20090511BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100226

17Q First examination report despatched

Effective date: 20100611

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 573119

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ACORDA THERAPEUTICS, INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006031769

Country of ref document: DE

Effective date: 20121018

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MURGITROYD AND COMPANY, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2393748

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20121227

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 573119

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120829

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120829

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121229

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121231

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121129

26N No opposition filed

Effective date: 20130530

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006031769

Country of ref document: DE

Effective date: 20130530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060926

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20210927

Year of fee payment: 16

Ref country code: IT

Payment date: 20210922

Year of fee payment: 16

Ref country code: FR

Payment date: 20210927

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20210927

Year of fee payment: 16

Ref country code: DE

Payment date: 20210929

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20211001

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20211004

Year of fee payment: 16

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006031769

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20220926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220926

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230401

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220930

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20231027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220926

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220927